Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study

被引：0

作者：

Marmorino, Federica

Cremolini, Chiara

Loupakis, Fotios

Barbara, Cecilia

Dargenio, Francesco

Miraglio, Emanuela

Masi, Gianluca

Salvatore, Lisa

Marcucci, Lorenzo

Antonuzzo, Lorenzo

Chiara, Silvana

Banzi, Chiara

Schirripa, Marta

Amoroso, Domenico

Bonetti, Andrea

Martignetti, Angelo

Paris, Myriam

Boni, Luca

Tomcikova, Daniela

Falcone, Alfredo

机构：

[1] Azienda Osped Univ Pisana, UO Oncol Med 2, Ist Toscano Tumori, Pisa, Italy

[2] Azienda Osped Univ Pisana, Ist Toscano Tumori, Pisa, Italy

[3] Ist Toscano Tumori, Pisa, Italy

[4] Osped Civile Livorno, Dept Med Oncol, Livorno, Italy

[5] AUSL 6 Livorno, Dipartimento Oncol, Piombino, Italy

[6] S Croce Gen Hosp, Dept Oncol, Cuneo, Italy

[7] UO Oncol Med Azienda Toscana Nord Ovest, Dipartimento Oncol, Pontedera, Italy

[8] Azienda Osped Univ Careggi, Florence, Italy

[9] Natl Inst Canc Res, Genoa, Italy

[10] Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy

[11] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA, Italy

[12] Osped Versilia, Lido Di Camaiore, Italy

[13] Dept Med Oncol, Legnago, Italy

[14] Unita Operat Oncol Med, Siena, Italy

[15] Osped Inferm Biella, SOC Oncol, Biella, Italy

[16] Ist Toscano Tumori, AOU Careggi, Clin Trial Coordinating Ctr, Florence, Italy

[17] Fdn Sandro Pitigliani, Peato, Italy

[18] UO Oncol Med 2 Univ, Pisa, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.e15127

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15127

引用

页数：2

共 50 条

[21] FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC).
Salvatore, Lisa
Loupakis, Fotios
Cremolini, Chiara
Schirripa, Marta
Antoniotti, Carlotta
Marmorino, Federica
Zoratto, Federica
Bergamo, Francesca
Brunetti, Isa Maura
Pfanner, Elisabetta
Masi, Gianluca
Genovesi, Dario
Filidei, Elena
Giorgetti, Assuero
Falcone, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[22] FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.
Cremolini, Chiara
Antoniotti, Carlotta
Stein, Alexander
Bendell, Johanna C.
Gruenberger, Thomas
Masi, Gianluca
Ongaro, Elena
Hurwitz, Herbert
Falcone, Alfredo
Schmoll, Hans-Joachim
Di Maio, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] Response to the first-line FOLFOX plus bevacizumab (BEV) therapy to predict responses to the subsequent therapies and survival in the BEV beyond progression (BBP) strategy for metastatic colorectal cancer: A retrospective analysis of CCOG-0801 study
Nakayama, Goro
Uehara, Keisuke
Hayashi, Naomi
Tanaka, Chie
Kobayashi, Daisuke
Kanda, Mitsuro
Yamada, Suguru
Fujii, Tsutomu
Sugimoto, Hiroyuki
Koike, Masahiko
Nomoto, Shuji
Fujiwara, Michitaka
Ando, Yuichi
Kodera, Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[24] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
Stein, Alexander
Atanackovic, Djordje
Hildebrandt, Bert
Stuebs, Patrick
Steffens, Claus-Christoph
Brugger, Wolfram
Hapke, Gunnar
Illerhaus, Gerald
Bluemner, Ernst
Bokemeyer, Carsten
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[25] Efficacy and safety of bevacizumab (BEV) plus chemotherapy in Chinese patients (pts) with metastatic colorectal cancer (mCRC): Results from the ARTIST study.
Guan, Z.
Xu, J.
Luo, R.
Feng, F.
Wang, L.
Shen, L.
Yu, S.
Ba, Y.
Liang, J.
Wang, D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[26] Tumor VEGFA gene expression is associated with serum lactate dehydrogenase (LDH) levels and intratumoral mRNA expression of genes involved in glycolysis in patients with metastatic colorectal cancer (mCRC).
Azuma, M.
Shi, M. M.
Jacques, C. J.
Barrett, C.
Danenberg, K. D.
Iqbal, S.
El-Khoueiry, A.
Yang, D.
Zhang, W.
Lenz, H.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 153S - 153S
[27] Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181
Peeters, M.
Price, T. J.
Strickland, A. H.
Ciuleanu, T. E.
Scheithauer, W.
O'Reilly, S.
Keane, M. M.
Spigel, D. R.
Tian, Y.
Krishnan, K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[28] RANDOMISED PHASE III STUDY OF BEVACIZUMAB plus CHEMOTHERAPY BEYOND PROGRESSION IN BEVACIZUMAB-TREATED PATIENTS WITH METASTATIC COLORECTAL CANCER: TML STUDY KRAS SUBGROUP FINDINGS
Van Cutsem, Eric
Maria Vieitez, Jose
Bouche, Olivier
Osterlund, Pia
Bennouna, Jaafar
Andre, Thierry
Sastre, Javier
Alonso-Orduna, Vicente
Kubicka, Stefan
Greil, Richard
von Moos, Roger
Reyes-Rivera, Irmarie
Scherer, Stefan
Bendahmane, Belguendouz
Arnold, Dirk
ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
[29] Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV plus FOLFIRI versus BEV plus XELIRI (FNCLCC ACCORD 13/0503 study)
Ducreux, M.
Adenis, A.
Mendiboure, J.
Francois, E.
Boucher, E.
Chauffert, B.
Ychou, M.
Pierga, J.
Montoto-Grillot, C.
Conroy, T.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[30] Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
Yin, Chenxi
Jiang, Chang
Liao, Fangxin
Rong, Yuming
Cai, Xiuyu
Guo, Guifang
Qiu, Huijuan
Chen, Xuxian
Zhang, Bei
He, Wenzhuo
Xia, Liangping
ONCOTARGETS AND THERAPY, 2014, 7 : 1415 - 1422

← 1 2 3 4 5 →